Description
Retatrutide – Synthetic triple agonist peptide targeting GLP-1, GIP, and glucagon receptors. 10mg lyophilized vial.
Research Profile
- Investigated in preclinical and clinical models for interactions with incretin hormone receptor signaling pathways
- Subject of studies examining simultaneous GLP-1R, GIPR, and glucagon receptor activation in animal models
- Studied in vitro for binding affinity and receptor selectivity profiling
- Not approved for human use
For in vitro research and laboratory use only. Not for human or veterinary use.
Reviews
There are no reviews yet.